Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Kortenberg – page 21

1 955 clinical trials in Kortenberg, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Kortenberg at a glance
1 955
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 955 trials in Kortenberg

Open in trial search

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

A study to evaluate the safety and effectiveness of H-CYS(SS)-GLU-VAL-SER-GLN-LEU-LEU-LYS-GLY-ASP-ALA-CYS(SS)-OH in patients with advanced solid tumors who have completed other treatments.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:TAX2
  • Sponsor:Apmonia Therapeutics

A safety study of romosozumab in children and adolescents with osteogenesis imperfecta

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Romosozumab
  • Sponsor:Amgen Inc.

Acute leukaemia

Recruiting

A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Enzomenib
  • Sponsor:Sumitomo Pharma America Inc.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Centre Leon Berard

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Stemline Therapeutics Inc.

Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AZD4144
  • Sponsor:AstraZeneca AB

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Glaxosmithkline Research & Development Limited

A Study of S-606001 Added to Enzyme Replacement Therapy for Patients with Late-Onset Pompe Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:MZE001
  • Sponsor:Shionogi B.V.

Cardiac failure+1

Recruiting

A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Kortenberg

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. The trials aim to evaluate alternative treatment approaches for managing functional dyspepsia and related conditions.

  • PPI Deprescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Strategies

The research explores on-demand medication use and alternative therapeutic options using alginate formulations, comparing their effectiveness with traditional tapering methods.

02 Digestive Health Studies

Clinical investigations examining treatment optimization for heartburn and reflux conditions. The research focuses on developing evidence-based approaches to reduce long-term medication dependency.

  • Symptom Management
  • Treatment Optimization
  • Medication Reduction Strategies

These trials aim to establish more effective approaches to managing digestive health while minimizing long-term medication use.

03 Primary Care Innovation

Primary care-focused research evaluating novel approaches to medication management in chronic conditions. The studies emphasize patient-centered strategies for reducing unnecessary long-term medication use.

  • Patient-Centered Care
  • Chronic Medicine Management
  • Evidence-Based Deprescribing

This research aims to transform primary care practices by establishing optimal deprescribing protocols for commonly used medications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.